Diabetes research and clinical practice最新文献

{"title":"Effects on calcium phosphate homeostasis after sodium-glucose cotransporter 2 inhibitor in patients with advanced chronic kidney disease and type 2 diabetes mellitus","authors":"Gordon Chun Kau Chan ,&nbsp;Jack Kit Chung Ng ,&nbsp;Cheuk Chun Szeto ,&nbsp;Kai Ming Chow","doi":"10.1016/j.diabres.2024.111818","DOIUrl":"10.1016/j.diabres.2024.111818","url":null,"abstract":"<div><h3>Background</h3><p>The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on calcium phosphate homeostasis in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) remain uncertain.</p></div><div><h3>Methods</h3><p>A retrospective observational cohort study of patients with T2DM at CKD stage G3b-5ND who received SGLT2i as compared to control from 1 January 2015 through 31 December 2021 was recruited. Propensity score assignment at 1:3 ratio by logistic regression was done. All patients were followed for 12 months. Outcomes were changes in phosphate level.</p></div><div><h3>Results</h3><p>We analyzed 1,450 SGLT2i users and 4,350 control subjects. At the 12^th month, SGLT2i users had a slower increase in phosphate levels (absolute change: −0.01 ± 0.28 vs + 0.14 ± 0.34 mmol/L; percentage change: −0.74 % ± 25.56 vs + 10.88 ± 28.15 %, <em>P</em> for both &lt; 0.001). The proportion of patients with high phosphate was lower with SGLT2i (8.2 % vs 24.6 % increase). In the generalized estimating equation, SGLT2i was linked to a longitudinal reduction in phosphate (B −0.039, <em>P</em>&lt;0.001).</p></div><div><h3>Conclusions</h3><p>SGLT2i can effectively slow down the progression of phosphate retention in advanced CKD with T2DM.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"216 ","pages":"Article 111818"},"PeriodicalIF":6.1,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practicalities and importance of assessing urine albumin excretion in type 2 diabetes: A cutting-edge update","authors":"Katarina Lalić ,&nbsp;Ljiljana Popović ,&nbsp;Sandra Singh Lukač ,&nbsp;Iva Rasulić ,&nbsp;Ana Petakov ,&nbsp;Milica Krstić ,&nbsp;Marija Mitrović ,&nbsp;Aleksandra Jotić ,&nbsp;Nebojša M Lalić","doi":"10.1016/j.diabres.2024.111819","DOIUrl":"10.1016/j.diabres.2024.111819","url":null,"abstract":"<div><p>Type 2 diabetes (T2D) is associated with increased risk for chronic kidney disease (CKD). It is estimated that 40 % of people with diabetes have CKD, which consequently leads to increase in morbidity and mortality from cardiovascular diseases (CVDs). Diabetic kidney disease (DKD) is leading cause of CKD and end-stage renal disease (ESRD) globally. On the other hand, DKD is independent risk factor for CVDs, stroke and overall mortality. According to the guidelines, using spot urine sample and assessing urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) are both mandatory methods for screening of CKD in T2D at diagnosis and at least annually thereafter. Diagnosis of CKD is confirmed by persistent albuminuria followed by a progressive decline in eGFR in two urine samples at an interval of 3 to 6 months. However, many patients with T2D remain underdiagnosed and undertreated, so there is an urgent need to improve the screening by detection of albuminuria at all levels of health care. This review discusses the importance of albuminuria as a marker of CKD and cardiorenal risk and provides insights into the practical aspects of methods for determination of albuminuria in routine clinical care of patients with T2D.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"215 ","pages":"Article 111819"},"PeriodicalIF":6.1,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucose lowering drug or strategy dependent impact of weight reduction on the prevention of CVD outcomes in Type 2 diabetes: a systematic review of CVOTs","authors":"Nebojša M. Lalić ,&nbsp;Aleksandra Jotić ,&nbsp;Ljiljana Lukić ,&nbsp;Tanja Miličić ,&nbsp;Marija Maćešić ,&nbsp;Jelena Stanarčić Gajović ,&nbsp;Milica Stoiljković ,&nbsp;Mina Milovančević ,&nbsp;Djurdja Rafailović Cvetković ,&nbsp;Katarina Lalić","doi":"10.1016/j.diabres.2024.111816","DOIUrl":"10.1016/j.diabres.2024.111816","url":null,"abstract":"<div><h3>Aims</h3><p>This systematic review was aimed to assess the association between magnitude of body weight loss (BWL) in type 2 diabetes (T2D) patients and cardiovascular (CV) risk in CV outcome trials (CVOTs).</p></div><div><h3>Methods</h3><p>We searched electronic databases (PubMed, Cochrane and Scopus) for available CVOTs, observational cohort studies or post hoc analyses of clinical trials of adult T2D patients investigated the association of BWL with CV outcomes and/or all-cause mortality.</p></div><div><h3>Results</h3><p>19 RCTs of novel glucose-lowering drugs (GLP-1RA, DPP-4i and SGLT2i) and 6 RCT or observational trial of different strategies (intensive treatment or standard care) were included (379.904 T2D patients). Higher BWL during GLP-1RA treatment, in comaprison to lower BWL, was associated with higher decrease in risk of MACE, while DPP-4i had not that effect. With SGLT2i the higher decrease in risk of MACE was associated with lower BWL. In contrast, in other different strategies, higher BWL lead to increase in risk for MACE and all-cause mortality.</p></div><div><h3>Conclusions</h3><p>In CVOTs, treatment of T2D patients resulted in BWL, which correlated with reduction in risk for CV outcomes, particularly with GLP-1 RAs. However, interventional non-CVOTs are warning that in the absence of structured behavioral intervention and relevant medication, the large BWL might be harmful for CV outcomes.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"216 ","pages":"Article 111816"},"PeriodicalIF":6.1,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD","authors":"Santo Colosimo ,&nbsp;Hamish Miller ,&nbsp;Dimitrios A. Koutoukidis ,&nbsp;Thomas Marjot ,&nbsp;Garry D. Tan ,&nbsp;David J. Harman ,&nbsp;Guruprasad P. Aithal ,&nbsp;Pinelopi Manousou ,&nbsp;Roberta Forlano ,&nbsp;Richard Parker ,&nbsp;David A. Sheridan ,&nbsp;Philip N. Newsome ,&nbsp;William Alazawi ,&nbsp;Jeremy F. Cobbold ,&nbsp;Jeremy W. Tomlinson","doi":"10.1016/j.diabres.2024.111820","DOIUrl":"10.1016/j.diabres.2024.111820","url":null,"abstract":"<div><h3>Objectives</h3><div>Currently, non-invasive scoring systems to stage the severity of non-alcoholic fatty liver disease (NAFLD) do not consider markers of glucose control (glycated haemoglobin, HbA1c); this study aimed to define the relationship between HbA1c and NAFLD severity in patients with and without type 2 diabetes.</div></div><div><h3>Research design and methods</h3><div>Data were obtained from 857 patients with liver biopsy staged NAFLD. Generalized-linear models and binomial regression analysis were used to define the relationships between histological NAFLD severity, age, HbA1c, and BMI. Paired biopsies from interventional studies (n = 421) were used to assess the impact of change in weight, HbA1c and active <em>vs</em>. placebo treatment on improvements in steatosis, non-alcoholic steatohepatitis (NASH), and fibrosis.</div></div><div><h3>Results</h3><div>In the discovery cohort (n = 687), risk of severe steatosis, NASH and advanced fibrosis correlated positively with HbA1c, after adjustment for obesity and age. These data were endorsed in a separate validation cohort (n = 170). Predictive modelling using HbA1c and age was non-inferior to the established non-invasive biomarker, Fib-4, and allowed the generation of HbA1c, age, and BMI adjusted risk charts to predict NAFLD severity. Following intervention, reduction in HbA1c was associated with improvements in steatosis and NASH after adjustment for weight change and treatment, whilst fibrosis change was only associated with weight change and treatment.</div></div><div><h3>Conclusions</h3><div>HbA1c is highly informative in predicting NAFLD severity and contributes more than BMI. Assessments of HbA1c must be a fundamental part of the holistic assessment of patients with NAFLD and, alongside age, can be used to identify patients with highest risk of advanced disease.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"217 ","pages":"Article 111820"},"PeriodicalIF":6.1,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of major candidate protein biomarkers and long-term diabetic kidney disease progression among Asians with young-onset type 2 diabetes mellitus","authors":"Tan Si Hua Clara ,&nbsp;Zheng Huili ,&nbsp;Liu Jian-Jun ,&nbsp;Sylvia Liu ,&nbsp;Lee Wei Lun Janus ,&nbsp;Kee Kai Xiang ,&nbsp;Resham Lal Gurung ,&nbsp;M. Yiamunaa ,&nbsp;Ang Kue Loong Keven ,&nbsp;Shao Yi-Ming ,&nbsp;Tavintharan Subramaniam ,&nbsp;Sum Chee Fang ,&nbsp;Lim Su Chi","doi":"10.1016/j.diabres.2024.111821","DOIUrl":"10.1016/j.diabres.2024.111821","url":null,"abstract":"<div><h3>Aims</h3><p>We aim to determine the association of seven major candidate protein biomarkers and diabetic kidney disease (DKD) progression among Asians with young-onset type 2 diabetes mellitus (T2DM).</p></div><div><h3>Methods</h3><p>824 T2DM patients (onset ≤ 40 years old) were classified as DKD progressors based on yearly estimated glomerular filtration rate (eGFR) decline of &gt;3 ml/min/1.73 m² or &gt;40 % from baseline. Plasma leucine-rich α-2-glycoprotein 1 (pLRG1), tumor necrosis factor-receptor 1 (pTNF-R1), pigment epithelium-derived factor (pPEDF), urinary α-1-microglobulin (uA1M), kidney injury molecular 1 (uKIM-1), haptoglobin (uHP) and uromodulin (uUMOD) were measured using enzyme-linked immunoassays.</p></div><div><h3>Results</h3><p>Over 5.7 years of follow-up, 25.2 % of patients were DKD progressors. Elevated levels of pLRG1, pTNF-R1, pPEDF, uA1M, uKIM-1 and uHP were associated with DKD progression. The association between pTNF-R1 levels and DKD progression persisted after adjusting for clinical covariates (OR 1.84, 95 %CI 1.44–2.34, p &lt; 0.001). The effects of pTNF-R1 were partially mediated through hyperglycemia (8 %) and albuminuria (10 %). Inclusion of pTNF-R1 in a clinical variable-based model improved the area under the receiver operating characteristics curve for predicting DKD progression by 0.02, from 0.72 (95 %CI 0.68–0.76) to 0.74 (95 %CI 0.70–0.78), p = 0.099.</p></div><div><h3>Conclusions</h3><p>Among seven major candidate proteins, pTNF-R1, partially mediated through hyperglycemia and albuminuria, robustly predicted DKD progression among Asians with young-onset T2DM.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"216 ","pages":"Article 111821"},"PeriodicalIF":6.1,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between temperatures and type 2 diabetes: A prospective study in UK Biobank","authors":"ShengYuan Wang ,&nbsp;YaTing Lei ,&nbsp;XiaoLi Wang ,&nbsp;Kun Ma ,&nbsp;Cheng Wang ,&nbsp;ChangHao Sun ,&nbsp;TianShu Han","doi":"10.1016/j.diabres.2024.111817","DOIUrl":"10.1016/j.diabres.2024.111817","url":null,"abstract":"<div><h3>Objective</h3><p>This study aims to prospectively examine the association between temperatures and the occurrence of type 2 diabetes (T2D).</p></div><div><h3>Methods</h3><p>We used the CPH models to analyze 103,215 non-diabetic participants in the UK Biobank cohort who answered questions about workplace temperature, to evaluate the survival relationship, and the interaction effects of working environmental temperature and T2D-related genetic risk scores (GRS) on the occurrence of T2D. The occurrence of T2D was assessed by hospital inpatient records. The weighted T2D-related GRS were calculated.</p></div><div><h3>Results</h3><p>During 1,355,200.6 person-years follow-up, a total of 2436 participants were documented as having diagnosed T2D. After adjustment, compared to the comfortable group, the participants working in non-comfortable environmental temperature had greater risk of T2D (HR: 1.27, 95 %CI: 1.04 to 1.55, for cold; HR: 1.32, 95 %CI: 1.17 to 1.48 for hot; HR: 1.51, 95 %CI: 1.38 to 1.65 for alternate). Similarly, individuals exposed to different levels of genetic risk scores in alternating hot and cold work environments had a higher risk of developing type 2 diabetes.</p></div><div><h3>Conclusions</h3><p>This study found working in single non-comfortable environmental temperatures was associated with greater risk of T2D occurrence, and exposure to alternating environmental temperatures had the highest risk of range and severity.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"215 ","pages":"Article 111817"},"PeriodicalIF":6.1,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"β-cell function and long-term glycemic control in patients newly diagnosed with type 2 diabetes with moderate hyperglycemia after a 6-month course of basal insulin therapy","authors":"Chin-Sung Kuo ,&nbsp;Harn-Shen Chen","doi":"10.1016/j.diabres.2024.111814","DOIUrl":"10.1016/j.diabres.2024.111814","url":null,"abstract":"<div><h3>Aims</h3><p>To evaluate whether treatment with insulin is advantageous compared with oral anti-diabetic drugs (OAD) for patients newly diagnosed with type 2 diabetes with moderate hyperglycemia.</p></div><div><h3>Methods</h3><p>Patients newly diagnosed with type 2 diabetes with moderate hyperglycemia were recruited and randomized to receive insulin, metformin or sitagliptin treatment. The oral glucose tolerance test (OGTT) was performed before treatment and 6 months thereafter. The primary outcome was the glycohemoglobin (HbA1c) level change. For the secondary efficacy analysis, the β-cell function and insulin sensitivity were calculated from the OGTT, as was the proportion of subjects who reached the treatment target (HbA1c level &lt; 7.0 % or &lt; 6.5 %) at 6 months.</p></div><div><h3>Results</h3><p>We randomized 50 patients to the three groups and 32 patients who received the allocated treatment were analyzed. The change of HbA1c level in the insulin, metformin, and sitagliptin groups was − 2.06 ± 1.37 %, −0.43 ± 0.32 %, and − 1.62 ± 0.92 %, respectively. This change was smallest in the metformin group. There was no significant difference in the changes or final HbA1c levels between the insulin and sitagliptin groups. The treat-to-target (HbA1c level &lt; 7.0 %) rates in the insulin, metformin and sitagliptin were 75 %, 50 % and 100 %, respectively. The treat-to-target rates were not significantly different among the three groups. The insulin secretion indices, including the Matsuda index and HOMA-IR, indicated that the groups did not differ after 6 months of therapy.</p></div><div><h3>Conclusion</h3><p>A 6-month course of basal insulin therapy did not benefit patients newly diagnosed with diabetes with moderate hyperglycemia in terms of insulin sensitivity or insulin secretion.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"215 ","pages":"Article 111814"},"PeriodicalIF":6.1,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141912214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adolescent-Preferred financial incentives to promote type 1 diabetes Self-Care: A discrete choice experiment","authors":"Davene R. Wright ,&nbsp;Tom Chen ,&nbsp;Kristen D. Chalmers ,&nbsp;Seema K. Shah ,&nbsp;Joyce P. Yi-Frazier ,&nbsp;Jessica L. LeBlanc ,&nbsp;Katharine Garvey ,&nbsp;Kirsten D. Senturia ,&nbsp;Catherine Pihoker ,&nbsp;Faisal S. Malik","doi":"10.1016/j.diabres.2024.111798","DOIUrl":"10.1016/j.diabres.2024.111798","url":null,"abstract":"<div><h3>Aims</h3><p>This study aimed to quantify preferences for the characteristics of a financial incentives program that would motivate adolescent engagement in type 1 diabetes (T1D) self-care.</p></div><div><h3>Method</h3><p>We performed a discrete choice experiment with 12–18 year-olds with T1D from two pediatric hospital endocrinology clinics (n = 317). We identified key attributes of incentives: (1) monthly value of the reward, (2) payment structure, and (3) difficulty of incentivized behaviors. In twelve choice questions, adolescents chose the incentive option from a pair of profiles that was more likely to motivate them to increase adherence to recommended self-care. Options presented were tailored to adolescents’ T1D technology use and perceived difficulty of completing each behavior. We analyzed data using a conditional logit model.</p></div><div><h3>Results</h3><p>The value of the reward accounted for 60.8% of preferences. Adolescents were willing to accept lower value rewards when incentive payments used positive vs. negative reinforcement (−$10.88 (95% CI: −$12.60, −9.24)) and preferred higher incentives for performing hard vs. easier behaviors (+$14.92 (95% CI: +$12.66, +$17.28)).</p></div><div><h3>Conclusions</h3><p>Stated preferences can inform intervention design. Future research will evaluate the external validity of the discrete choice experiment-informed intervention design by assessing adolescent health and behavioral outcomes in a randomized controlled trial.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"215 ","pages":"Article 111798"},"PeriodicalIF":6.1,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First year national Swedish paediatric Hba1c data are at the level of several intervention studies: Results from a Swedish nationwide diabetes register study","authors":"Isabelle I.K. Steineck ,&nbsp;Johan Anderzén ,&nbsp;Katarina Eeg-Olofsson ,&nbsp;Jan Ekelund ,&nbsp;Soffia Gudbjörnsdottir ,&nbsp;Lena Hanberger ,&nbsp;Jonatan Nåtman ,&nbsp;Auste Pundziute Lyckå ,&nbsp;Ulf Samuelsson ,&nbsp;Stefan Särnblad ,&nbsp;Karin Åkesson ,&nbsp;Ragnar Hanas","doi":"10.1016/j.diabres.2024.111807","DOIUrl":"10.1016/j.diabres.2024.111807","url":null,"abstract":"<div><h3>Aims/hypothesis</h3><p>To study the progression of HbA1c after diagnosis of type 1 diabetes in children and adolescents during 2010–2019 with emphasis on HbA1c nadir 3–6 months after onset.</p></div><div><h3>Methods</h3><p>Partial funding was secured for this study. The Swedish paediatric diabetes quality register SWEDIABKIDS has &gt;95 % coverage of type 1 diabetes up to 18 years. A mixed model for repeated measurements was used to estimate differences in HbA1c between onset year periods.</p></div><div><h3>Results</h3><p>We followed 6,891 patients over two years from onset (48,292 HbA1c values). We found a gradual decrease in mean HbA1c 24 months after onset from 56.0 mmol/mol (7.28 %) in 2010/11 to 50.5 mmol/mol (6.77 %) in 2018/19, which is at the level of several recent intervention studies. The initial drop in HbA1c from onset until 3 and 6 months has become more pronounced in recent years. There was a significant positive correlation between HbA1c at 3 and 6 months with 12, 18 and 24 months. Percentage of severe hypoglycaemic coma was higher (5.1 % vs 3.4 %; p = 0.023) in 2010/2011 than 2018/2019, but the absolute risk of ketoacidosis was essentially unchanged, (1.5 % to 0.8 %, p = 0.110)</p></div><div><h3>Conclusions/interpretation</h3><p>There was a continuous decrease in HbA1c over the study period 2010–2019, which coincides in time with an increased use of diabetes technology and lowering the HbA1c target to 48 mmol/mol (6.5 %). The decrease in 2-year HbA1c was preceded by a lower HbA1c nadir, which may set the trajectories for coming HbA1c and be a modifiable factor for a long-term improvement in metabolic control.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"216 ","pages":"Article 111807"},"PeriodicalIF":6.1,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0168822724007174/pdfft?md5=f8754368f8487717a15ea26bbd6c7ec9&pid=1-s2.0-S0168822724007174-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis","authors":"Laura D Lomeli ,&nbsp;Alimitha M Kodali ,&nbsp;Yumiko Tsushima ,&nbsp;Adi E Mehta ,&nbsp;Kevin M Pantalone","doi":"10.1016/j.diabres.2024.111806","DOIUrl":"10.1016/j.diabres.2024.111806","url":null,"abstract":"<div><p>Glucagon-like peptide-1 receptor agonists (GLP-1RA) have been reported to increase the risk of acute pancreatitis (AP). This real-world study did not observe a higher frequency of AP with GLP-1RA exposure in adults with T2D and a prior history of AP regardless of etiology.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"215 ","pages":"Article 111806"},"PeriodicalIF":6.1,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0168822724007162/pdfft?md5=27059595f804694c0871717e8b9e6d74&pid=1-s2.0-S0168822724007162-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}